Vaxcyte is expected to post a Q3 2026 loss of $1.84 per share on revenue of $12.50 million, while its current share price of $62.61 trades at a significant discount to the $117.30 average analyst target.
Investors are primarily focused on the detailed safety profile and regulatory submission timeline for VAX-31 following its successful Phase 3 OPUS-1 trial results in October 2026. The company’s robust cash position of approximately $2.5 billion provides a multi-year runway as it transitions toward a planned Biologics License Application (BLA) for its lead pneumococcal vaccine. Analysts will also scrutinize quarterly R&D expenses to gauge the burn rate as Vaxcyte prepares for the commercial scale-up of its vaccine franchise.